engleski

Immunological Aspects and Anti-Amyloid Strategy for Alzheimers Dementia

Alzheimer’s dementia (AD) is the most common form of dementia among the elderly, accounting for at least two-thirds of all dementia cases. Its global prevalence is estimated at 24 million cases, which certainly represents a costly burden. Amyloid beta or Aβ plaques and neurofibrillary tangles define AD pathologically but do not fully explain this disease ; it also involves inflammation as well as neuronal, axonal, and synaptic loss and dysfunction. Amyloid plaques are surrounded by activated microglia, cytokines, and complement components, which is suggestive of inflammation, an important component of AD pathophysiology. For the diagnosis of AD, cerebrospinal fluid markers, especially in vivo amyloid measurements, contribute to an accurate assessment of AD pathology and differential diagnosis. Aβ levels are a very good marker for the presence of amyloid deposits in the brain, while total tau and phosphorylated tau are useful for the detection of neurodegeneration. The implementation of anti-amyloid therapy and other disease-modifying interventions may have immense clinical impact if initiated at an early or presymptomatic stage of AD, i.e. before significant brain damage occurs. This paper briefly reviews the abovementioned topic and provides recommendations for future studies.

Alzheimers disease; amyloid beta; plaques; anti-amyloid therapy; inflammation

nije evidentirano